Comparative Pharmacology
Head-to-head clinical analysis: TELMISARTAN versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TELMISARTAN versus TEVETEN HCT.
TELMISARTAN vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin II receptor antagonist; selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
40 mg orally once daily; range 20-80 mg/day
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Clinical Note
moderateTelmisartan + Benzydamine
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Benzydamine."
Clinical Note
moderateTelmisartan + Droxicam
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Droxicam."
Clinical Note
moderateTelmisartan + Loxoprofen
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Loxoprofen."
Clinical Note
moderateTelmisartan + Clonixin
Terminal half-life is approximately 24 hours (range 20–30 hours), supporting once-daily dosing without significant accumulation.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Primarily biliary-fecal (approximately 97% unchanged in feces); renal excretion accounts for <1% of the dose.
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Clonixin."